GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Healios KK (TSE:4593) » Definitions » COGS-to-Revenue

Healios KK (TSE:4593) COGS-to-Revenue : 0.76 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Healios KK COGS-to-Revenue?

Healios KK's Cost of Goods Sold for the three months ended in Mar. 2025 was 円29.0 Mil. Its Revenue for the three months ended in Mar. 2025 was 円38.0 Mil.

Healios KK's COGS to Revenue for the three months ended in Mar. 2025 was 0.76.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Healios KK's Gross Margin % for the three months ended in Mar. 2025 was 23.68%.


Healios KK COGS-to-Revenue Historical Data

The historical data trend for Healios KK's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Healios KK COGS-to-Revenue Chart

Healios KK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.10 0.23

Healios KK Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.14 - 0.76

Healios KK COGS-to-Revenue Calculation

Healios KK's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=128 / 560
=0.23

Healios KK's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=29 / 38
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Healios KK  (TSE:4593) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Healios KK's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 29 / 38
=23.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Healios KK COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Healios KK's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Healios KK Business Description

Traded in Other Exchanges
Address
World Trade Center Bldg. 15th Floor, 2-4-1 Hamamatsucho, Minato-ku, Tokyo, JPN, 105-6115
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy.

Healios KK Headlines

No Headlines